Canada: Update On The Review Of Neonicotinoids By The Canadian Pest Management Regulatory Agency

In Canada, pesticides are regulated by Health Canada's Pest Management Regulatory Agency (the "PMRA") on behalf of the Minister of Health and under the authority of the Pest Control Products Act (the "PCPA"). Health Canada announced a further consultation in its ongoing assessment of a group of pesticides known as neonicotinoids. Introduced commercially in the 1990s with a wide variety of uses, this group of pesticides has gained international attention in the last decade and has recently come under closer scrutiny by Canada’s PMRA.

Health Canada routinely re-examines pesticides that are registered in Canada to ensure they continue to meet modern safety standards for human health and the environment. There are two post-registration processes by which the PMRA can undertake these examinations: “re-evaluation” (s.16 of the PCPA) and “special reviews” (s.17 of the PCPA).

A “re-evaluation” of registered pesticides is conducted by Health Canada on a cyclical basis, every 15 years or sooner, to determine whether the use of these products continues to be acceptable according to current standards. During a re-evaluation, PMRA reviews available scientific information on the product before proposing a decision, including information provided by pesticide registrants, other federal or provincial departments and information published in scientific literature.

A “special review” is provided for under the PCPA to determine the continued acceptability of the health and environmental risks of a product and its value. The PCPA requires the PMRA to initiate a “special review” of a registered pest control product when there are reasonable grounds to believe that the health or environmental risks of the product are, or its value is, unacceptable.

In response to the global attention on neonics, in 2012 the PMRA decided to undertake a re evaluation of the three key neonicotinoids currently approved for agricultural use in Canada, namely imidacloprid, clothianidin, and thiamethoxam. In addition to the re-evaluation, aquatic environmental special reviews are also underway for clothianidin and thiamethoxam.


i. Aquatic Environmental Re-Evaluation

Amongst other things, in 2012, Health Canada announced its intentions to undertake an environmental assessment of imidacloprid to determine how it interacts with aspects of the environment, including aquatic life such as fish, insects, and other organisms. The proposed re evaluation decision for imidacloprid was published on November 23, 2016. This assessment concluded that, in aquatic environments in Canada, imidacloprid is being measured at levels that are harmful to certain aquatic insects, which act as a food source for fish, birds and other animals.

The aquatic environmental assessment resulted in a recommendation of a phase-out of imidacloprid over the next three to five years for all agricultural and a majority of other outdoor uses, having determined that, under current conditions of use, the environmental risks for most products containing imidacloprid do not meet current safety standards.

A human health risk assessment was included in the re-evaluation and found no human health concerns from any exposure routes, when used according to the applicable labels. Risks to bees and other pollinators were not a part of this re-evaluation, but instead the PMRA initiated a separate risk assessment specific to pollinators.

ii. Pollinator Re-Evaluation

Health Canada then conducted a re-evaluation of all agricultural, turf and ornamental uses for imidacloprid and its associated end-use products, specifically to assess the risk to pollinators. The risk assessment consisted of characterizing the exposure and effects of imidacloprid to bees, and determining whether exposures resulting from its uses are expected to pose a risk.

The evaluation was conducted according to the Guidance for Assessing Pesticide Risks to Bees, which was collectively developed by the PMRA, the United States Environmental Protection Agency (USEPA) and the California Department of Pesticide Regulation. A preliminary pollinator risk assessment was published in January 2016 that did not point to unacceptable risks to managed honey bees provided strict precautions to limit exposure were followed.

Further data was submitted to the PMRA by the registrants of the products containing imidacloprid and the PMRA reviewed additional available information from open scientific literature. On May 31, 2018, the Proposed Re-evaluation Decision PRVD2018-12 was released and presented the proposed regulatory decision, including suggested risk mitigation measures to further protect pollinators. Based on its scientific evaluation, Health Canada proposed: (i) to phase out certain uses of imidacloprid; (ii) to provide direction on when foliar applications may be done; and (iii) to require additional label statements for seed treatment of cereal and legume crops to minimize bee exposure to dust during planting of treated seed.

Health Canada completed this consultation on August 29, 2018. A final decision by Health Canada that will integrate both imidacloprid re-evaluations (i.e., the aquatic environmental assessment and the pollinator assessment) is anticipated in December 2018.

Clothianidin and Thiamethoxam

i. Aquatic Environmental Special Review

During the re-evaluation of imidacloprid, Health Canada identified that clothianidin and thiamethoxam also occurred frequently and at comparable levels to imidacloprid in certain Canadian waterbodies that were exposed to intensive agriculture. Given the similarities these two neonics have to imidacloprid, in November 2016, Health Canada initiated special reviews for clothianidin and thiamethoxam, starting with an environmental assessment in aquatic environments.

On August 15, 2018, Health Canada published its preliminary recommendations on whether to phase out specific uses for these two neonics, having determined, as with imidacloprid that, in aquatic environments in Canada, both clothianidin and thiamethoxam are being measured at concentrations that are harmful to aquatic insects.

In the proposed special review decisions, Health Canada is proposing to phase-out—over the next three to five years—all outdoor uses of both neonics on food and feed crops, including seed treatments, and on turf (for clothianidin) and outdoor ornamentals (for thiamethoxam). The PMRA will consider alternate risk management proposals, provided that they can achieve acceptable levels in the environment within the same timeframe.

The proposed special review decisions are currently open for public consultation from August 15, 2018, to November 13, 2018. The PMRA has indicated that, once it considers the comments and any information received during the public consultation period, it will publish a final decision.

ii. Pollinator Re-Evaluation

Health Canada conducted a re-evaluation of all agricultural and ornamental uses for thiamethoxam and clothianidin (and their associated end-use products), specifically to assess the risk to pollinators. On December 19, 2017, it published the Proposed Re-evaluation Decision for both neonics.[AK23]  Based on its review, the PMRA concluded that an application of pesticides containing both neonics can lead to effects that may impact the survival of bee colonies or solitary bee species and, as such, it is proposing a phase out of certain applications for a variety of crops for both products. The final decisions are expected to be published in late 2018.


Canada is not alone in scrutinizing neonicotinoids. Governments worldwide are taking significant regulatory action, including a registration review by the USEPA for imidacloprid, clothianidin and thiamethoxam. In Europe, the European Food Safety Authority (EFSA) published an updated risk assessment for all three neonics in February 2018 and concluded that overall, neonics represent a risk to bees. Based on this risk assessment, in April 2018, Member States of the European Union endorsed the European Commission’s proposals to ban all outdoor uses of imidacloprid, thiamethoxam, and clothianidin. In Ontario, which enacted strict regulations in July 2015 to regulate the sale and use of treated seeds, the Grain Farmers of Ontario have recently called for a lifting of the regulations in light of the uncertainty surrounding future or continued registration of neonicotinoids in Canada.

We will continue to monitor the PMRA processes and anticipate learning in December 2018 what new regulatory measures Canada will adopt.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions